Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05737277
Other study ID # GAB-IBSPED
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date July 1, 2023

Study information

Verified date February 2023
Source Azienda Ospedaliera "Sant'Andrea"
Contact Giovanni Di Nardo, Prof
Phone 00393397267637
Email giovanni.dinardo@uniroma1.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder (FGID) characterized by recurrent episodes of defecation related abdominal pain associated with abnormal bowel habit. Several studies have reported significant alterations in the gut microbiota that may promote the development and persistence of IBS. Some Bifidobacterium species, mainly Bifidobacterium adolescentis, have a documented immunomodulatory effect and can modulate visceral hypersensitivity or improve the integrity of the intestinal epithelium barrier thorough its well-known ability to produce g-aminobutyric acid Thus, designed a randomised, double-blind, placebo-controlled, parallel-arm study evaluating the efficacy and safety of Bifidobacterium adolescentis PRL2019 on abdominal pain symptoms in pediatric patients with Irritative bowel sindorom


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gabapral
This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS). The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period.
Placebo
This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS). The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera "Sant'Andrea"

Outcome

Type Measure Description Time frame Safety issue
Primary Rome IV criteria The primary outcome will be the improve in the abdominal pain symptoms (frequency and severity) according to validated score from baseline to the end of the treatment period. 2 months
Secondary bristol stool scale Secondary outcomes will be modifications of bowel habits and safety. 6 months
See also
  Status Clinical Trial Phase
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Completed NCT01981954 - A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) Phase 3
Completed NCT02199626 - SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Phase 4
Recruiting NCT04679792 - Postual Control in Pediatric Chiari I Malformation
Recruiting NCT06061159 - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction Phase 4
Active, not recruiting NCT05453968 - Berotralstat Treatment in Children With Hereditary Angioedema Phase 3
Not yet recruiting NCT02182648 - Bispectral Index Guiding Etomidate Used in Children Aged 3 to 10 for Clinical Anesthesia Induction Phase 4
Active, not recruiting NCT04176640 - Quantifying Brain Injury on Computed Tomography in Hospitalized Children
Active, not recruiting NCT06146452 - Micronutrient Status in Pediatric Palliative Care
Completed NCT04041180 - Impact on the Length of Stay in Incentive Spirometry and Pain in the Decompensation of Sickle Cell Disease: .
Not yet recruiting NCT06165003 - Examination of Nurses' Use of Broselow Tape in Non-resuscitation Pediatric Emergency Department Practices N/A
Recruiting NCT02286297 - Pediatric Endotracheal Intubation During Resuscitation N/A
Unknown status NCT00613184 - Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses N/A
Recruiting NCT00265772 - Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Phase 4
Completed NCT04106063 - A New Speech, Spatial, and Qualities of Hearing Scale Short-Form for Deaf Children
Not yet recruiting NCT06376643 - Augmented Reality to Support Cardiopulmonary Resuscitation N/A
Not yet recruiting NCT05511233 - ERAS Protocol in Newborns: CARES Study N/A
Not yet recruiting NCT04127968 - Efficacy and Safety of Vitamin A Treatment for Children With Sepsis N/A
Active, not recruiting NCT04472286 - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Recruiting NCT04988516 - Virtual Reality Distraction for Anxiety (VR-IMAGINE) N/A